

# Special Issue

## HPV Immunotherapy

### Message from the Guest Editor

Infection with high-risk human papilloma viruses (HPV) is the causative agent of cervical cancer and is associated with other anogenital malignancies and head and neck cancers. Novel therapeutic approaches to control HPV cancers are of wide interest since, despite the implementation of an effective vaccination program, HPV cancer burden is still very high. Immunotherapy aimed at strengthening the host immune system response against tumor cells has shown promise in HPV malignancies. However, benefits are limited for some patients, urging more efforts in this area. The focus of this Research Topic is to collect articles, reviews or case reports covering different aspects of HPV cancers and immunology that shed light on potential innovative therapeutic options, such as, but not limited to:

- Immunotherapy and delivery systems;
- Tumor/immune system crosstalk;
- Strategies to re-educate immune cells;
- Biomarkers to follow and predict response to immune therapies.

---

### Guest Editor

Dr. Domenico Mattoscio

Center for Advanced Studies and Technology, Department of Medical, Oral and Biotechnology Science, "G. d'Annunzio" University of Chieti - Pescara, Chieti, Italy

---

### Deadline for manuscript submissions

closed (31 May 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/61558](https://mdpi.com/si/61558)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).